NDC product
Cleocin Phosphate
NDC 0009-5095 · Pharmacia & Upjohn Company LLC
Key facts
| Product NDC | 0009-5095 |
|---|---|
| Proprietary name | Cleocin Phosphate |
| Nonproprietary name | clindamycin phosphate |
| Substances | CLINDAMYCIN PHOSPHATE |
| Dosage form | INJECTION, SOLUTION |
| Route | INTRAMUSCULAR, INTRAVENOUS |
| Labeler | Pharmacia & Upjohn Company LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA050441 |
| Pharmacologic classes | Decreased Sebaceous Gland Activity [PE], Lincosamide Antibacterial [EPC], Lincosamides [CS], Neuromuscular Blockade [PE] |
| Marketing start | Nov 18, 2019 |
| Marketing end | Oct 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory